The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 2, 2013, Pages 167-173

  Andersen, Asger ^a   Nielsen, Jan M ^a   Holmboe, Sarah ^a   Vildbrad, Mads D ^a   Nielsen Kudsk, Jens E ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

heart failure; hypertrophy; phosphodiesterase inhibitors; pulmonary hypertension; Right heart

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; GUANYLATE CYCLASE; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE COURSE; ENZYME INHIBITION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE OVERLOAD; INOTROPISM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; VENOUS RETURN;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CYCLIC GMP; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HEART FAILURE; HEART VENTRICLES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; PYRAZOLES; PYRIDINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONES; SURVIVAL ANALYSIS;

EID: 84883305305     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318294a1cf     Document Type: Article

References (32)

1. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med. 2003;24:273-286.
2. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:78S-92S.
3. Takimoto E, Champion HC, Belardi D, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. 2005;96:100-109.
4. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci U S A. 2001;98:2703-2706.
5. Borgdorff MA, Bartelds B, Dickinson MG, et al. Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle. Eur J Heart Fail. 2012;14:1067-1074.
6. Andersen A, Nielsen JM, Peters CD, et al. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail. 2008;10:1158-1165.
7. Schäfer S, Ellinghaus P, Janssen W, et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res. 2009;82:30-39.
8. Ghofrani H, Voswinckel R, Gall H. Riociguat for pulmonary hypertension. Future Cardiol. 2010;6:155-166.
9. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39-45.
10. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999; 29:297-310.
11. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
12. Stasch JP, Dembowsky K, Perzborn E, et al. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol. 2002;135:344-355.
13. Hardziyenka M, Campian ME, de Bruin-Bon HA, et al. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiogr. 2006;19:1272-1279.
14. Urboniene D, Haber I, Fang YH, et al. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2010;299:L401-L412.
15. Saville DJ. Multiple comparison procedures: The practical solution. Am Stat. 1990;44:174-180.
16. Ghio S, Klersy C, Magrini G, et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol. 2010;140:272-278.
17. Faber MJ, Dalinghaus M, Lankhuizen IM, et al. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: Correlations with the degree of hypertrophy. Proteomics. 2005;5:2519-2530.
18. Bogaard HJ, Natarajan R, Henderson SC, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009;120:1951-1960.
19. Nagayama T, Hsu S, Zhang M, et al. Pressure-overload magnitudedependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol. 2009;46:560-567.
20. Nagayama T, Zhang M, Hsu S, et al. Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther. 2008;326: 380-387.
21. Takimoto E, Koitabashi N, Hsu S, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119: 408-420.
22. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
23. Thorsen LB, Eskildsen-Helmond Y, Zibrandtsen H, et al. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. Eur J Pharmacol. 2010;647:147-154.
24. Olson EN. A decade of discoveries in cardiac biology. Nat Med. 2004; 10:467-474.
25. Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007;116:238-248.
26. Shan X, Quaile MP, Monk JK, et al. Differential expression of PDE5 in failing and non-failing human myocardium. Circ Heart Fail. 2012;5:79-86.
27. Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: Structural deterioration and compensatory mechanisms. Circulation. 2003;107: 984-991.
28. Masuyama H, Tsuruda T, Sekita Y, et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res. 2009;32:597-603.
29. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol. 1985;25:171-191.
30. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123:2263-2273.
31. Wu J, Bu L, Gong H, et al. Effects of heart rate and anesthetic timing on high-resolution echocardiographic assessment under isoflurane anesthesia in mice. J Ultrasound Med. 2010;29:1771-1778.
32. Roth DM, Swaney JS, Dalton ND, et al. Impact of anesthesia on cardiac function during echocardiography in mice. Am J Physiol Heart Circ Physiol. 2002;282:H2134-H2140.